This is a non-interventional medical chart review study aiming to examine the treatment patterns, effectiveness, and safety of ceftazidime-avibactam in approximately 12 countries (including but not limited to Austria, France, Germany, Greece, Italy, Spain, United Kingdom, Russia, Argentina, Colombia, Brazil, and Mexico), with possible expansion to other countries as ceftazidime-avibactam is launched. Eligible patients are adults who have been treated with ceftazidime-avibactam in routine practice at participating sites since 01 January, 2018 onwards or since the date of launch in the country if it is posterior to 01 January, 2018. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants Who Received at Least One Dose of Ceftazidime-Avibactam Classified According to Type of Usage as Monotherapy or Combination Therapy: FAS 72+ Population
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Number of Participants Who Received at Least One Dose of Ceftazidime-Avibactam Classified According to Type of Usage as Monotherapy or Combination Therapy: FAS72- Population
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Total and Daily Dose of Ceftazidime-Avibactam: FAS72+ Population
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Total and Daily Dose of Ceftazidime-Avibactam: FAS72- Population
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Total Duration of Administration of Ceftazidime-Avibactam: FAS72+ Population
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Total Duration of Administration of Ceftazidime-Avibactam: FAS72- Population
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Number of Participants Whose Samples Were Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: Microbiology Outcomes Dataset (MOD) Population
Timeframe: From end of index therapy up to 60 days after hospital discharge, in-hospital death, withdrawal from study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Type of Specimen Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: MOD Population
Timeframe: From end of index therapy up to 60 days after hospital discharge, in-hospital death, withdrawal from study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Timeframe: After treatment initiation up to 60 days post hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Timeframe: After treatment initiation up to 60 days post hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Timeframe: After treatment initiation up to 60 days post hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Type of Clinical Evaluation Outcome at Initial Hospitalization: Clinical Outcomes Dataset (COD) Population
Timeframe: At initial hospitalization (from the data evaluated in approximately 40 months of this study)
Number of Participants Classified According to Type of Clinical Evaluation Outcome 60 Days Post-Discharge: Clinical Outcomes Dataset (COD) Population
Timeframe: 60 days after hospital discharge (from the data evaluated in approximately 40 months of this study)
Number of Participants Classified According to Type of Clinical Evaluation Outcome 60 Days Post-Treatment: Clinical Outcomes Dataset (COD) Population
Timeframe: 60 days post treatment (from the data evaluated in approximately 40 months of this study)
Number of Participants With Microbiological Treatment Outcome as Success: MOD Population
Timeframe: Up to 14 days post first dose of ceftazidime-avibactam (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Antibiotics Used for Current Infection Before Ceftazidime-Avibactam: FAS72+ Population
Timeframe: Up to 90 days prior to index date (from the data evaluated in approximately 40 months of this study)
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
Timeframe: Up to 90 days prior to index date (from the data evaluated in approximately 40 months of this study)
Percentage of Participants Who Died During Index Hospitalization
Timeframe: During index hospitalization, maximum of 418 days (from the data evaluated in approximately 40 months of this study)
Percentage of Participants Who Died Within the 30 Days After Hospital Discharge (Including In-Hospital Mortality): FAS72+ Population
Timeframe: From index treatment up to 30 days post hospital discharge, maximum of 434 days (from the data evaluated in approximately 40 months of this study)
Percentage of Participants Who Died Within 60 Days After Hospital Discharge (Including In-Hospital Mortality): FAS72+ Population
Timeframe: From index treatment up to 60 days post hospital discharge, maximum of 434 days (from the data evaluated in approximately 40 months of this study)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)
Duration of Hospital Stay: FAS72+ Population
Timeframe: From index date up to hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 418 days (from the data evaluated in approximately 40 months of the study)
Total Duration of ICU Stay: FAS72+ Population
Timeframe: During index hospitalization, maximum up to 418 days (from the data evaluated in approximately 40 months of the study)
Number of Participants Readmitted to the Hospital During the 30 Days After Initial Discharge: FAS72+ Population
Timeframe: Up to 30 days after initial discharge (from the data evaluated in approximately 40 months of the study)
Number of Participants Readmitted to the Hospital During the 60 Days After Initial Discharge: FAS72+ Population
Timeframe: Up to 60 days after initial discharge (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to Reason for Readmission to the Hospital: FAS72+ Population
Timeframe: At readmission to the hospital, up to maximum of 60 days post initial hospital discharge (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to the Healthcare Resource Utilized During the Hospitalization: FAS72+ Population
Timeframe: During index hospitalization maximum of 418 days (from the data evaluated in approximately 40 months of the study)
Number of Participants Classified According to All Wards Attended During Hospitalization: FAS72+ Population
Timeframe: During index hospitalization maximum of 418 days (from the data evaluated in approximately 40 months of the study)